Health In Tech (NASDAQ: HIT) reported a wider-than-expected quarterly loss for the second quarter of 2026, signaling continued pressure on profitability despite strategic initiatives aimed at expanding its distribution network. The company posted an earnings per share (EPS) of $(0.04), which missed the analyst consensus estimate of $(0.03) by 100 percent. This result reflects a sharp deterioration from the $0.01 per share earnings recorded in the same period last year.

On the topline, Health In Tech demonstrated resilience against market expectations in absolute terms but faced year-over-year declines. Quarterly sales reached $8.1 million, beating the analyst consensus estimate of $7.547 million. However, this figure represents a 13.50 percent decline compared to the $9.314 million recorded in the corresponding period of the previous fiscal year. Management attributed this dip primarily to a timing shift in policy effective dates caused by onboarding a new carrier partner, rather than a change in underlying demand.

Strategic Metrics and Guidance

To provide a clearer picture of business momentum beyond GAAP accounting constraints, the company emphasized non-GAAP metrics. Contracted revenue—defined as revenue contractually committed under active policies but not yet recognized under GAAP—amounted to $32.3 million for the first half of 2026. Of this total, $17.3 million was already recognized as GAAP revenue in the first half, with the remaining $14 million expected in the second half of the year and $1 million in 2027.

Additionally, pipeline revenue stood at $66.3 million as of July 31. Management noted that with five more months remaining in 2026, the expanded sales team aims to convert a portion of this pipeline into contracted revenue. Supported by these figures and an increase in distribution partners to 933 (up 19.9% year-over-year), the company reaffirmed its full-year 2026 revenue guidance of $45 million to $50 million.

Operational Investments and Balance Sheet

The wider loss reflects ongoing investments in sales, marketing, and technology. Total operating expenses for the quarter were $7.3 million, up from $5.6 million in the same period last year. Sales and marketing expenses rose to $2.2 million from $1.2 million, while general and administrative expenses increased to $4.3 million from $3.8 million. Adjusted EBITDA was negative $1.3 million for the quarter, compared to positive $1.6 million in the prior-year period.

Despite the operational losses, the balance sheet remains healthy. The company ended the quarter with $6.5 million in cash and cash equivalents and $11.8 million in working capital, an improvement from $8.1 million in cash and $9.5 million in working capital a year ago. Operating cash used improved to $2.9 million in the second quarter compared to $3.3 million in the first quarter, reflecting discipline in working capital management.

What the Numbers Show

The divergence between the revenue beat against estimates and the year-over-year decline highlights the impact of structural changes within the business. While the company generated more revenue than analysts anticipated ($8.1 million vs $7.547 million), the 13.5% drop from the prior year’s $9.314 million underscores the friction caused by the carrier transition.

Furthermore, the significant increase in operating expenses ($7.3 million vs $5.6 million last year) outpaced the top-line performance, driving the adjusted EBITDA into negative territory (-$1.3 million). This suggests that while demand indicators like contracted revenue ($32.3 million for H1) remain robust, the immediate financial impact is being absorbed through higher investment in growth infrastructure, including the upcoming launch of the Hitrix platform for the large-group self-funded stop-loss market.

Existing Snippets: []

Health In Tech reaffirmed its FY2026 sales guidance, maintaining the range at $45.000 million to $50.000 million. The reaffirmation comes against an analyst estimate of $46.813 million, placing the consensus forecast within the company's guided band.

FY2026 sales guidance at a glance

The following table summarises Health In Tech's affirmed sales outlook against the prevailing analyst estimate.

The company made no change to its previously stated guidance range, reaffirming the $45.000 million to $50.000 million band for FY2026. The analyst consensus of $46.813 million falls within this range, indicating the estimate is broadly aligned with management's outlook.